Therapeutics News and Research

RSS

New Alzheimer's studies show advances against different treatment targets

Two studies related to experimental Alzheimer's therapies reported positive results today at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD 2008) in Chicago.

28 Jul 2008

New human tissue bank

The University of Bradford has unveiled a new facility to provide UK biomedical researchers access to a wide range of human tissue and tissue products.

28 Jul 2008

Advanced Cancer Therapeutics licenses technology to develop HPV vaccine

Advanced Cancer Therapeutics (ACT) has announced the signing of two new collaborative agreements that will advance development of the Company's novel human papillomavirus (HPV) vaccine program.

23 Jul 2008

Roche starts acquisition process of ARIUS - fast tracks access to screening platform for antibody therapeutics

Roche and ARIUS Research Inc. have announced that the two companies have signed a definitive agreement for Roche to acquire ARIUS in an all-cash transaction at a price of approximately C$191 million.

23 Jul 2008

Roche acquires Mirus to advance RNAi delivery research

Roche (Basel) and Mirus Bio Corporation (Madison, WI, USA) announced today that they have entered into a definitive agreement under which Roche will acquire Mirus Bio Corporation, a privately-owned US company based in Madison, Wisconsin, that focuses on the discovery and development of innovative nucleic acid based technologies, including a proprietary RNAi (Ribonucleic Acid interference) delivery platform.

22 Jul 2008

Stem cell chicken and egg debate moves to unlikely arena: the testes

Logic says it has to be the niche. As air and water preceded life, so the niche, that hospitable environment that shelters adult stem cells in many tissues and provides factors necessary to keep them young and vital, must have emerged before its stem cell dependents.

20 Jul 2008

New center for protein therapeutics formed by UB pharmaceutical scientists

Pharmaceutical researchers at the University at Buffalo have joined forces with scientists from several of the world's largest pharmaceutical companies to tackle fundamental research questions that need to be answered to advance development of promising protein-based drugs.

15 Jul 2008

Gene silencer and quantum dots reduce protein production to a whisper

More than 15 years ago, scientists discovered a way to stop a particular gene in its tracks. The Nobel Prize-winning finding holds tantalizing promise for medical science, but so far it has been difficult to apply the technique, known as RNA interference, in living cells.

9 Jul 2008

Nanoparticles detect telomerase activity

Telomerase, an enzyme that prevents chromosomes from shortening when they divide, is widely suspected of playing a key role in making cancer cells immortal.

9 Jul 2008

Nanocantilevers image nanoparticles in cells

Borrowing from a Nobel Prize-winning technique credited with starting the nanotechnology revolution, a team of researchers from Oak Ridge National Laboratory (ORNL) and Northwestern University's Nanomaterials for Cancer Diagnostics and Therapeutics has developed a method for imaging nanoparticles inside of cells.

9 Jul 2008

Discovery of new function for an old enzyme in sialidosis

The lack of a single protein usually thought of as a run-of-the-mill enzyme that helps to recycle molecules in cells causes an incurable and often fatal disease of children, according to St. Jude Children's Research Hospital investigators.

7 Jul 2008

Jefferson scientists discover way to immunize mice against metastatic disease

Taking advantage of the fact that the intestines have a separate immune system from the rest of the body, scientists at the Kimmel Cancer Center at Jefferson in Philadelphia have found a way to immunize mice against the development of metastatic disease.

24 Jun 2008

Quantum dots stop RNA interference in living cells

More than 15 years ago scientists discovered a way to stop a particular gene in its tracks. The Nobel Prize-winning finding holds tantalizing promise for medical science, but so far it has been difficult to apply the technique, known as RNA interference, in living cells.

24 Jun 2008

New hope for patients with breast cancers resistant to tamoxifen

Researchers have found a new family of therapeutic agents that interferes with the ability of estrogen to stimulate the growth of breast cancer cells. The results of the new study will be presented by Nicole Patterson at The Endocrine Society's 90th Annual Meeting in San Francisco.

16 Jun 2008

Computer predicts anti-cancer molecules

A new computer-based method of analyzing cellular activity has correctly predicted the anti-tumour activity of several molecules.

16 Jun 2008

VistaGen Therapeutics announces new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor cells

VistaGen Therapeutics, Inc., a biotechnology company using leading-edge embryonic stem cell (ES Cell) technologies for predictive toxicology and drug discovery, has announced new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor cells. VistaGen has exclusive rights for commercial use in its ES Cell-based tools platform for drug discovery and development.

16 Jun 2008

Compugen announces discovery of novel drug targets for cancer antibody therapeutics

Compugen Ltd. announced today the discovery of more than ten novel targets of antibody therapy for various types of solid and hematopoietic cancer.

11 Jun 2008

Without increased funding, California's dominance and public health are threatened, according to new report

The California Healthcare Institute (CHI) and PricewaterhouseCoopers (PwC) today released a report, "The National Institutes of Health: Fueling Healthcare Innovation in California," urging legislators to support increased funding for the National Institutes of Health (NIH) - the backbone of the biomedical industry in California, which employs more than 267,000 people in high wage jobs.

11 Jun 2008

Boehringer, Gilead freeze antiretroviral prices for some U.S. agencies

Pharmaceutical companies Boehringer Ingelheim and Gilead Sciences are freezing the prices of their antiretroviral drugs for select agencies in the U.S., the AIDS Healthcare Foundation announced on Tuesday, Bloomberg reports.

8 Jun 2008

Boehringer Ingelheim, Gilead to freeze AIDS drug price

AIDS Healthcare Foundation (AHF) today applauded decisions by Boehringer Ingelheim (BI) and Gilead Sciences, Inc. to freeze prices on antiretroviral medications purchased by government agencies.

3 Jun 2008